Related Experiment Videos
Stroke prevention therapies and management of patient subgroups
1Department of Neurology, University of Pennsylvania Medical Center, Philadelphia.
Insights
Stroke prevention is crucial. Ticlopidine shows superior efficacy over aspirin for preventing recurrent strokes, especially within the first year after an event.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Public Health
Background:
- Stroke is a leading cause of death in the US, necessitating effective prevention strategies.
- Current efforts in reversing acute cerebral ischemia face significant barriers.
- Primary and secondary prevention are key to reducing stroke incidence and recurrence.
Purpose of the Study:
- To review the importance of stroke prevention.
- To evaluate the efficacy of antiplatelet agents in secondary stroke prevention.
- To discuss current challenges and individualized therapy approaches.
Main Methods:
- Review of existing clinical trials and therapeutic guidelines.
- Comparison of antiplatelet agents like aspirin and ticlopidine.
- Assessment of the role of anticoagulants such as warfarin.
Main Results:
- Ticlopidine demonstrated superior efficacy compared to aspirin in preventing recurrent strokes.
- The benefit of ticlopidine was particularly noted in the first year post-stroke.
- Dipyridamole has not proven effective for stroke prevention.
Conclusions:
- Secondary stroke prevention is vital, with antiplatelet therapy playing a significant role.
- Ticlopidine offers a more effective option than aspirin for preventing recurrent strokes.
- Individualized treatment strategies are essential for optimal stroke prevention outcomes.
Abstract:
Stroke is the third leading cause of death in the United States. Efforts directed at reversing acute cerebral ischemia are promising but are hampered by multiple logistic and physiologic barriers. Prevention of stroke, therefore, remains of critical importance. Primary prevention is accomplished through reduction of risk factors and the appropriate use of warfarin or aspirin in patients with cardiac sources of emboli such as atrial fibrillation. Secondary prevention is designed to reduce the risk of stroke in patients with known stroke precursors, including transient ischemia, reversible ischemic deficits, and completed stroke. Aspirin and ticlopidine are two antiplatelet agents with an established role in secondary stroke prevention. In a major North American clinical trial, ticlopidine demonstrated superior efficacy to aspirin for the prevention of recurrent stroke, particularly in the first year following a stroke. Dipyridamole has not been shown to be useful for stroke prevention. The role of warfarin in the prevention of recurrent noncardiogenic stroke remains controversial and is currently under investigation. Stroke prevention remains an important challenge, and therapy should be individualized to achieve optimal results.